Dermatomyositis Induced by Hepatitis B Virus-related Hepatocellular Carcinoma: A Case Report and Review of the Literature

Jen-Wei Chou¹,², Yin-Lan Lin³, Ken-Sheng Cheng¹,², Po-Yuan Wu¹,⁴ and Teressa Reanne Ju³

Abstract

Dermatomyositis or polymyositis as a paraneoplastic syndrome of hepatocellular carcinoma (HCC) is an uncommon event. Few cases have been reported in the literature. We herein report the case of a 55-year-old man with chronic hepatitis B and alcoholism who presented with skin rash. Abdominal computed tomography revealed multiple hypervascular liver tumors consistent with HCC. He subsequently developed dysphagia with proximal limb weakness. Laboratory tests and electromyography demonstrated inflammatory myopathy. We therefore diagnosed the patient with HCC-induced dermatomyositis. Prednisolone and anti-viral therapy were administered; however, the patient died two months later due to the progression of the disease. We review the cases of HCC-induced dermatomyositis and polymyositis in the literature.

Key words: dermatomyositis, hepatitis B virus, hepatitis C virus, hepatocellular carcinoma, paraneoplastic syndrome, polymyositis

(Intern Med 56: 1831-1837, 2017) (DOI: 10.2169/internalmedicine.56.7595)

Introduction

Dermatomyositis and polymyositis are idiopathic inflammatory myopathies that are associated with muscle weakness and inflammatory infiltration within the skeletal muscle. The pathogenesis and etiology of both diseases are still unclear. It has been suspected that viral and autoimmune factors may be involved, and that an immune response against cancer may trigger an attack against the muscle components (1). The muscle damage associated with dermatomyositis is believed to be mediated by humoral factors directed against the endomysial capillary endothelial cells, while in polymyositis, cytotoxic T-cells mediate muscle fiber injury. Although the factors causing dermatomyositis or polymyositis remain to be elucidated, the relationship between inflammatory myopathies and viral infections or cancer has been reported in the literature (2-18). The tumors associated with dermatomyositis include ovarian cancer, breast cancer, melanoma, colon cancer and non-Hodgkin lymphoma (19); it is rarely associated with hepatocellular carcinoma (HCC). We herein report the case of a 55-year-old man of dermatomyositis induced by hepatitis B virus (HBV)-related HCC in Taiwan and review some cases of HCC-induced dermatomyositis and polymyositis in the English literature.

Case Report

A 55-year-old man with a history of alcoholism and who also was an HBV carrier, presented to our hospital due to tea-colored urine and yellow skin for 3 days. Moreover, he had exertional dyspnea and a poor appetite, but denied having weight loss. He had a family history of HCC and chronic hepatitis B (CHB).

Two weeks prior to his admission, he visited our dermatology clinic because of a generalized skin rash. A skin examination showed multiple erythematous patches over his...
scalf, face, and four limbs. Moreover, gottron rash, and erythematosus to violaceous raised papules overlying the metacarpals were noted (Fig. 1). Initially, delayed-type hypersensitivity, drug eruptions, and urticarial vasculitis were suspected. A skin biopsy was performed due to his poor response to treatment. A pathological examination of the skin biopsy specimen revealed mild vacuolar interface, mild superficial lymphohistiocytic and eosinophilic dermatitis consistent with an allergic cutaneous reaction or drug eruption without significant depositions of immunoglobulin (Ig) G, IgM, IgA, or C3. He was referred to our gastrointestinal clinic due to an impaired liver function. The serological examinations for viral hepatitis showed HBV surface antigen reactivity with a high viral load level of 5.19×10⁸ IU/mL (Table 1). He visited our emergency department due to his severe weakness and poor appetite.

Upon admission, a physical examination revealed anicteric scalp, face, trunk, and four limbs. Moreover, gottron rash, and erythematosus to violaceous raised papules overlying the metacarpals were noted (Fig. 1). Initially, delayed-type hypersensitivity, drug eruptions, and urticarial vasculitis were suspected. A skin biopsy was performed due to his poor response to treatment. A pathological examination of the skin biopsy specimen revealed mild vacuolar interface, mild superficial lymphohistiocytic and eosinophilic dermatitis consistent with an allergic cutaneous reaction or drug eruption without significant depositions of immunoglobulin (Ig) G, IgM, IgA, or C3. He was referred to our gastrointestinal clinic due to an impaired liver function. The serological examinations for viral hepatitis showed HBV surface antigen reactivity with a high viral load level of 5.19×10⁸ IU/mL (Table 1). He visited our emergency department due to his severe weakness and poor appetite.

Upon admission, a physical examination revealed anicteric scalp, face, trunk, and four limbs. Moreover, gottron rash, and erythematosus to violaceous raised papules overlying the metacarpals were noted (Fig. 1). Initially, delayed-type hypersensitivity, drug eruptions, and urticarial vasculitis were suspected. A skin biopsy was performed due to his poor response to treatment. A pathological examination of the skin biopsy specimen revealed mild vacuolar interface, mild superficial lymphohistiocytic and eosinophilic dermatitis consistent with an allergic cutaneous reaction or drug eruption without significant depositions of immunoglobulin (Ig) G, IgM, IgA, or C3. He was referred to our gastrointestinal clinic due to an impaired liver function. The serological examinations for viral hepatitis showed HBV surface antigen reactivity with a high viral load level of 5.19×10⁸ IU/mL (Table 1). He visited our emergency department due to his severe weakness and poor appetite.

Upon admission, a physical examination revealed anicteric scalp, face, trunk, and four limbs. Moreover, gottron rash, and erythematosus to violaceous raised papules overlying the metacarpals were noted (Fig. 1). Initially, delayed-type hypersensitivity, drug eruptions, and urticarial vasculitis were suspected. A skin biopsy was performed due to his poor response to treatment. A pathological examination of the skin biopsy specimen revealed mild vacuolar interface, mild superficial lymphohistiocytic and eosinophilic dermatitis consistent with an allergic cutaneous reaction or drug eruption without significant depositions of immunoglobulin (Ig) G, IgM, IgA, or C3. He was referred to our gastrointestinal clinic due to an impaired liver function. The serological examinations for viral hepatitis showed HBV surface antigen reactivity with a high viral load level of 5.19×10⁸ IU/mL (Table 1). He visited our emergency department due to his severe weakness and poor appetite.

Upon admission, a physical examination revealed anicteric scalp, face, trunk, and four limbs. Moreover, gottron rash, and erythematosus to violaceous raised papules overlying the metacarpals were noted (Fig. 1). Initially, delayed-type hypersensitivity, drug eruptions, and urticarial vasculitis were suspected. A skin biopsy was performed due to his poor response to treatment. A pathological examination of the skin biopsy specimen revealed mild vacuolar interface, mild superficial lymphohistiocytic and eosinophilic dermatitis consistent with an allergic cutaneous reaction or drug eruption without significant depositions of immunoglobulin (Ig) G, IgM, IgA, or C3. He was referred to our gastrointestinal clinic due to an impaired liver function. The serological examinations for viral hepatitis showed HBV surface antigen reactivity with a high viral load level of 5.19×10⁸ IU/mL (Table 1). He visited our emergency department due to his severe weakness and poor appetite.
Figure 2. Contrast-enhanced abdominal computed tomography. A: A 5-cm sized hypervascular tumor on the right lobe of the liver (arrow). B: A small hypervascular nodule was also identified on the right lobe of the liver (arrow). C: The tumor invaded the main portal vein (arrow). D: The tumor invaded the bilateral portal veins (arrows).

Complete blood tests and a biochemistry analysis are shown in Table 1. Contrast-enhanced abdominal computed tomography revealed cirrhosis with multiple hypervascular tumors of up to 5 cm in diameter on both lobes of the liver (Fig. 2A and B). Moreover, tumors invading the main portal vein and bilateral portal veins were also identified (Fig. 2C and D). We therefore made a clinical diagnosis of HCC with a staging of T3bN0M0. The patient’s skin symptoms improved after topical steroid treatment, but he complained of difficulty swallowing and muscle weakness. He had difficulty lifting his proximal limbs, limited squatting ability, and choking episodes, but denied slurred speech, double or blurred vision, sensory abnormalities, neck stiffness or headache. We consulted both a neurologist and a rheumatologist. A neurological examination revealed decreased proximal muscle tone and a lack of bilateral deep tendon reflexes. No muscle wasting or fasciculation was detected. A motor conduction study showed increased spontaneous activity with fibrillation, complex repetitive discharges, and positive sharp waves (Fig. 3). The voluntary motor units consist of low-amplitude polyphasic units of short duration. These findings were consistent with inflammatory myopathy. The patient’s highly elevated serum level of myoglobin and the results of other rheumatological tests are shown in Table 2. According to the Bohan and Peter criteria (1988), our patient was diagnosed to have dermatomyositis, favoring HCC-induced paraneoplastic syndrome. We initially prescribed intravenous hydrocortisone (200 mg, daily), then shifted to oral prednisolone (30 mg, daily). However, we tapered the prednisolone dose progressively due to the worsening of his liver function. In addition, we also prescribed an anti-viral agent, telbivudine (600 mg, daily). We advised the patient to undergo a liver biopsy and target therapy, but he refused. He developed profound jaundice, ascites, and hepatic encephalopathy. Two months later, the patient died due to the progression of his disease (Fig. 4).

Discussion

Dermatomyositis and polymyositis are idiopathic inflammatory myopathies that are characterized by muscle weakness and inflammatory infiltration within the skeletal muscle. The pathogenesis and etiology of both are still unclear. It has been suspected that viral and autoimmune factors may be involved, and that an immune response against cancer may trigger an attack against the muscle components (1). Humoral factors directed against endomysial capillary endo-
As for polymyositis, cytotoxic T-cells mediate muscle fiber injury causing endomysial inflammation. Although the factors causing dermatomyositis or polymyositis remain to be elucidated, the relationship between inflammatory myopathies and viral infection or cancer has been reported in the literature (2-18). The tumors that are associated with dermatomyositis include ovarian cancer, breast cancer, melanoma, colon cancer and non-Hodgkin lymphoma (19); it is less commonly associated with HCC. HCC is the leading cause of cancer death in Asia, including Taiwan. Chronic HBV or hepatitis C virus (HCV) infection is an important cause of cancer death in Asia, including Taiwan. Chronic HCV infection has been known to cause extrahepatic syndromes involving the organs, such as Grave’s disease or destructive thyroiditis, glomerular and tubulointerstitial renal involvement, porphyria cutanea tarda in the skin, as well as rheumatic diseases, such as Sjögren’s syndrome, rheumatoid arthritis, dermatomyositis, and polymyositis (25, 26). The extrahepatic symptoms of chronic HBV infection have also been well documented in the literature; these include renal involvement causing glomerulonephritis, membranoprolifera-
tive glomerulonephritis, and IgA nephropathy, and rheumatic diseases such as polyarteritis nodosa, anti-phospholipid syndrome, multiple sclerosis, and systemic lupus erythematosus (27).

Bohan established the diagnostic criteria for dermatomyositis and polymyositis in 1988 (28). Four of the five criteria were related to muscle disease (progressive, proximal, symmetrical weakness, an increased concentration of muscle enzymes, an abnormal electromyogram, and an abnormal muscle biopsy sample); the fifth was compatible with cutaneous disease. Over the years, modifications to the diagnostic criteria for idiopathic inflammatory myopathies have been proposed (29); however, there is still no formal international consensus. As of today, the diagnosis is based on the clinical and laboratory features, such as the characteristic muscle features, skin lesions, elevated levels of muscle enzymes such as creatine kinase, and myopathic changes on electromyography. The definitive diagnostic test is a muscle biopsy showing results that are consistent with the immunopathological findings of idiopathic inflammatory myopathy (29), and skin biopsy is recommended but not required. Gottron’s sign and mechanic’s hand are also considered diagnostic signs for dermatomyositis (30). Positive autoantibodies are helpful markers, but they are not required for the diagnoses of dermatomyositis or polymyositis. Anti-Jo 1 antibody has been found to be related to adenocarcinoma, particularly in the lung and breast (3). It is therefore highly specific but has low sensitivity for dermatomyositis (31). Our patient developed symmetrical proximal muscle weakness and skin rashes that were consistent with the classic clinical features of dermatomyositis. Electromyography showed increased spontaneous activity with fibrillation, complex repetitive discharges, and positive sharp waves. The voluntary motor units consist of low-amplitude polyphasic units of short duration. Both findings were consistent with inflammatory myopathic change. Although the patient refused to undergo muscle biopsy and the definitive diagnostic criteria
Figure 4. The patient’s clinical course with the clinical changes in liver and muscle enzymes.

could not be fulfilled, the other clinical and laboratorial findings in the patient were consistent with the above-mentioned criteria.

The first-line treatment for dermatomyositis or polymyositis is corticosteroids. Most authors suggest the initial use of an high-dose oral steroid with prednisolone 0.5 mg/kg per day or 60 mg per day, but variable response rates and complications may be seen (32-34). For refractory cases, pulsed intravenous methylprednisolone, immunosuppressants, intravenous immunoglobulin, and plasmapheresis are all advocated therapies for inflammatory myopathy. In our present case, the patient’s skin symptoms of dermatomyositis responded to treatment with intravenous, oral and topical steroids, but his muscle symptoms did not. Finally, we discontinued steroid treatment due to the worsening of his liver function.

Patients with CHB may undergo HBV reactivation, and their conditions are associated with potential morbidity and mortality during systemic glucocorticoid therapy if the therapy lasts for more than 6 months (18). In addition, a previous report recommends that such patients be monitored for an exacerbation of HBV during glucocorticoid therapy (35). In another case report of dermatomyositis induced by HBV-related HCC, the patient was treated with anti-viral therapy using lamivudine for the prevention of viral reactivation and high-dose steroids were used to treat the patient’s dermatomyositis symptoms. Anti-viral therapy is recommended in patients who are HBV carriers and who require long-term steroid therapy (18). However, the role of prophylactic anti-viral therapy in patients with CHB who require short-term steroid therapy remains unclear. In our case, we prescribed an anti-viral agent for the patient along with steroid therapy.

We reviewed sixteen cases (including the present case) of HCC-related dermatomyositis or polymyositis in the English literature. Our results are summarized in Table 3. The ratio of a synchronous diagnosis of dermatomyositis or polymyositis to HCC is 81%. The mean age of these patients was 56.3 years (range, 14 to 79 years). The ratio of dermatomyositis to polymyositis was 2.2:1 in these patients. The ratio of HBV to HCV infection in the documented case reports was 5:4. With regard to gender distribution, the ratio of males to females was 4.3:1 with a male predominance (81%). This lopsided gender ratio can be attributed to the difference in exposure to risk factors. Men are more likely to be infected with HBV and HCV, more frequently consume alcohol and cigarettes, and have a higher body mass than women. According to our results, we found that patients with HBV-related HCC had a significantly greater prevalence of dermatomyositis or polymyositis than those with HCV-related HCC. Moreover, patients with HCC-induced dermatomyositis or polymyositis had greater tumor volumes; the average tumor size in nine HCC patients with known data was 7.7 cm. In our study, we also reviewed the HCC staging of these patients according to the Barcelona-Clinic Liver Cancer (BCLC) classification. The percentages of patients with each of the BCLC stages were as follows: stage A, 6%; stage B, 44%, and stage C, 38%. There was a predominance of intermediate- and late-stage HCCs among these cases, indicating that the occurrence of dermatomyositis or polymyositis is a poor prognostic sign for HCC pa-
| References | Age/ Sex | Causes of HCC | Related inflammatory myopathy | ANA | Anti Jo-1 | Diagnosis of DM/ PM and HCC | HCC size and number | BCLC stage** | Management | Outcome |
|------------|----------|---------------|--------------------------------|-----|-----------|----------------------------|---------------------|--------------|------------|---------|
| 8          | 56/F     | ND            | DM                             | ND  | ND        | Synchronous                | ND                  | ND           | Steroid, chemotherapy | Died 15 months after diagnosis with DM |
| 6          | 36/M     | Not found     | DM                             | Negative | ND      | 5 weeks before diagnosis of HCC | ND                  | ND           | Steroid, chemotherapy | Died 14 days after diagnosis with DM |
| 14         | 14/M     | Not found     | DM                             | Positive | ND      | Synchronous                | ND                  | At least C (portal vein thrombosis) | Died 14 months after diagnosis with DM |
| 5          | 73/M     | HCV           | DM                             | Positive | Positive | Synchronous                | 8 cm, 1             | At least B | Steroid, azathioprine, TACE | Died 2 months after diagnosis with DM |
| 9          | 51/M     | HCV           | DM                             | Positive | Negative | Synchronous                | multiple            | At least C (N1) | Steroid, TACE, hepatectomy | Died 21 months after diagnosis with DM |
| 4          | 50/M     | HBV           | DM                             | ND  | ND        | 4 months after the diagnosis of HCC | 10 cm, 1           | At least B | Steroid, TACE, Systemic resection | Died 3 months after diagnosis with DM |
| 7          | 70/M     | ND            | PM                             | Negative | Negative | Synchronous                | 8 cm, 1             | At least B | Steroid            | Died 2 months after diagnosis with DM |
| 10         | 71/M     | HCV           | DM                             | Positive | Negative | Synchronous                | 6.5 cm, 1           | At least B | 50mg prednisolone/day then taper down, TACE | Died 3 months after diagnosis with DM |
| 17         | 79/F     | HCV           | DM                             | Positive | Negative | 9 months after the diagnosis of HCC | 6 cm, 1             | At least B | Steroid            | Died 2 months after diagnosis with DM |
| 11         | 58/M     | HBV           | DM                             | Positive | Negative | Synchronous                | 7 cm, 1             | At least C (portal vein thrombosis) | Died 2 months after diagnosis with PM |
| 13         | 50/F     | Not found     | PM                             | Positive | Negative | Synchronous                | 4.8 cm, 1           | At least A | High-dose steroid, liver lobectomy | Died 2 months after diagnosis with PM |
| 15         | 72/M     | Not found     | PM                             | ND  | ND        | Synchronous                | 12 cm, 1            | At least B | Steroid, NSAID | Died 4 months after diagnosis with PM |
| 18         | 55/M     | HBV           | DM                             | Positive | Negative | Synchronous                | 6.5 cm, 1           | At least B | High-dose steroid, Antiviral therapy | Died 5 months after diagnosis with PM |
| 16         | 56/M     | HBV           | PM                             | Negative | Negative | Synchronous                | (largest)12 cm, 3   | At least B | Steroid, lamivudine and TACE | Died 2 months after diagnosis with PM |
| 12         | 55/M     | Not found     | PM                             | Negative | Negative | Synchronous                | (largest)6 cm, 3    | At least C (N1) | Steroid            | Died 2 months after diagnosis with PM |
| Our case   | 55/M     | HBV           | DM                             | Negative | Negative | Synchronous                | 5 cm, multiple      | C (portal vein thrombosis) | Steroid            | Died 2 months after diagnosis with PM |

DM: dermatomyositis, PM: polymyositis, ND: not described, IVIG: intravenous immunoglobulin, TACE: transarterial chemoembolization, HCC: hepatocellular carcinoma. ** The BCLC stages of these patients are mainly based on their image findings due to incomplete laboratory data from the majority of the articles.
tients. The average survival time of 10 documented cases was seven months. However, there was one report that noted a remission from dermatomyositis after the resection of HCC (7).

In conclusion, from our experiences in this study, if a patient (especially late-stage male patients) with HCC presents with progressive proximal weakness and skin symptoms, then clinicians should consider the possibility of dermatomyositis.

The authors state that they have no Conflict of Interest (COI).

References

1. Kao LL, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon.Curr Rheumatol Rep 13: 225-232, 2011.
2. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polyomyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35: 438-444, 2008.
3. Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 2015 Oct 1 [Epub ahead of print].
4. Cheng TI, Tsou MH, Yang PS, Sung SM, Chuang VP, Sung JL. Dermatomyositis and erythrocytosis associated with hepatocellular carcinoma. J Gastroenterol Hepatol 17: 1239-1240, 2002.
5. Gomez A, Solans R, Simeon CP, et al. Dermatomyositis, hepato-carcinoma, and hepatitis C: comment on the article by Weidensaul et al. Arthritis Rheum 40: 394-395, 1997.
6. Gray RG, Altman RD, Gottlieb NL. Aberrant serum enzyme patterns in dermatomyositis associated with hepatica. J Rheumatol 3: 227-232, 1976.
7. Hasegawa K, Uesugi H, Kubota K, et al. Polyomyositis as a para-neoplastic manifestation of hepatocellular carcinoma. Hepatogastroenterology 47: 1425-1427, 2000.
8. Horie Y, Yamada M, Nakai K, et al. Combined hepatocellular-cholangiocarcinoma associated with dermatomyositis. J Gastroenterol Hepatol 4: 101-104, 1989.
9. Inuzuka M, Tomita K, Tokura Y, Takigawa M. Acquired ichthyosis associated with dermatomyositis in a patient with hepatocellular carcinoma. Br J Dermatol 144: 416-417, 2001.
10. Kee KM, Wang JH, Lee CM, Changchien CS, Eng HL. Chronic hepatitis C virus infection associated with dermatomyositis and hepato-cellular carcinoma. Chang Gung Med J 27: 834-839, 2004.
11. Kee SJ, Kim TJ, Lee SJ, et al. Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma. Rheumatol Int 29: 595-599, 2009.
12. Kim MJ, Kim JA, Sung MS, Min JK. Hepatocellular carcinoma, polyomyositis, rhabdomyolysis, and acute renal failure. J Korean Med Sci 19: 891-894, 2004.
13. Kishore D, Khurana V, Raj A, Gambhir IS, Diwaker A. Hepato-cellular carcinoma presenting as polyomyositis: a paraneoplastic syn-drome. Ann Saudi Med 31: 533-535, 2011.
14. Leauta-Labrez C, Perel Y, Toib A. Childhood dermatomyositis associated with hepatocarcinoma. N Engl J Med 333: 1083, 1995.
15. Tekaya R, Abdelghni K, Abdelmoula L, Ben Hadji Yahia C, Chaabouni L, Zouari R. Hepatocellular carcinoma with polyomyo-sitis as an initial symptom: a case report. Acta Clin Belg 66: 53-54, 2011.
16. Thanapirom K, Aniwant S, Treeprasertsuk S. Polyomyositis associated with hepatitis B virus cirrhosis and advanced hepatocellular carcinoma. ACG Case Rep J 1: 167-169, 2014.
17. Toshikuni N, Torigoe R, Mitsuana M, Omoto A, Nakashima K. Dermatomyositis associated with hepatocellular carcinoma in an elderly female patient with hepatitis C virus-related liver cirrhosis. World J Gastroenterol 12: 1641-1644, 2006.
18. Yang SY, Cha BK, Kim G, et al. Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma. Korean J Intern Med 29: 231-235, 2014.
19. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polyomyositis. A population-based study. N Engl J Med 326: 363-367, 1992.
20. Huang H, Hu XF, Zhao FH, Garland SM, Bhatla N, Qiao YL. Estimation of cancer burden attributable to infection in Asia. J Epidemiol 25: 626-638, 2015.
21. Shahmali A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol 26: 78-85, 2014.
22. Birrer RB, Birrer D, Klavins IV. Hepatocellular carcinoma and hepatitis virus. Ann Clin Lab Sci 33: 39-54, 2003.
23. Qu Q, Wang S, Chen S, Zhou L, Rui JA. Prognostic role and signifiance of paraneoplastic syndromes in hepatocellular carcinoma. Am Surg 80: 191-196, 2014.
24. Vautravers C, Rat P, Cercueil JP, Moreau T, Horiot JC, Chauffert B. Hepatocellular carcinoma presenting as paraneoplastic myasthe-nia gravis. Eur J Intern Med 19: e86-e87, 2008.
25. Coccoli P, Esposito P, Cianciaruso B, et al. Hepatitis C and kidney disease. Dig Liver Dis 39 Suppl 1: S83-S85, 2007.
26. Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 39 Suppl 1: S13-S21, 2007.
27. Maya R, Gershwin ME, Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol 34: 85-102, 2008.
28. Bohan A. History and classification of polyomyositis and dermatomyositis. Clin Dermatol 6: 3-8, 1988.
29. Cox S, Limaye V, Hill C, Blumbergs P, Roberts-Thomson P. Idio-pathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. Int J Rheum Dis 13: 117-124, 2010.
30. Sultan SM, Isenberg DA. Re-classifying myositis. Rheumatology (Oxford) 49: 831-833, 2010.
31. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2015 Sep 30 (Epub ahead of print).
32. Choy EH, Isenberg DA. Treatment of dermatomyositis and poly-myositis. Rheumatology (Oxford) 41: 7-13, 2002.
33. Aggarwal R, Odds CV. Therapeutic advances in myositis. Curr Opin Rheumatol 24: 635-641, 2012.
34. Bronner IM, van der Meulen MF, de Visser M, et al. Long-term outcome in polyomyositis and dermatomyositis. Ann Rheum Dis 65: 1456-1461, 2006.
35. Yang CH, Wu TS, Chiu CT. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 157: 587-590, 2007.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).